Iovance Biotherapeutics (NASDAQ:IOVA) Given New $8.00 Price Target at Citizens Jmp

Iovance Biotherapeutics (NASDAQ:IOVA) had its price objective increased by research analysts at Citizens Jmp from $5.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s price target would indicate a potential upside of 31.04% from the company’s previous close.

IOVA has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Barclays restated an “overweight” rating and set a $13.00 price objective on shares of Iovance Biotherapeutics in a report on Friday. Chardan Capital reduced their price target on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Citigroup restated an “outperform” rating on shares of Iovance Biotherapeutics in a report on Friday. Finally, Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a research note on Friday. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.75.

Iovance Biotherapeutics Trading Down 1.7%

Iovance Biotherapeutics stock traded down $0.10 during trading hours on Friday, reaching $6.11. 12,291,391 shares of the stock were exchanged, compared to its average volume of 15,458,137. The stock has a 50 day moving average of $4.35 and a two-hundred day moving average of $3.78. Iovance Biotherapeutics has a twelve month low of $1.76 and a twelve month high of $6.92. The company has a market cap of $2.73 billion, a P/E ratio of -6.48 and a beta of 0.71.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $198.63 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The company’s revenue was up 65.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.33) EPS. On average, analysts expect that Iovance Biotherapeutics will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Arcataur Capital Management LLC bought a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at $29,000. Granite Investment Partners LLC bought a new stake in shares of Iovance Biotherapeutics in the 4th quarter valued at about $29,000. Motley Fool Asset Management LLC purchased a new stake in Iovance Biotherapeutics during the 4th quarter valued at about $29,000. M&T Bank Corp bought a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $31,000. Finally, SBI Securities Co. Ltd. grew its position in Iovance Biotherapeutics by 169.1% during the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 7,269 shares during the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Record revenue and earnings beat: Iovance reported approximately $99.3 million in second-quarter revenue, up 66% year over year and 39% from the prior quarter. The $0.11 per-share loss was narrower than the $0.13 consensus estimate and substantially improved from a $0.33 loss a year earlier. Iovance second-quarter results
• Positive Sentiment: Amtagvi demand is driving growth: U.S. Amtagvi revenue reached roughly $91 million, while the authorized treatment-center network surpassed 95 locations and is expected to exceed 110 by year-end. Gross margin also improved to 56% as manufacturing efficiencies and cost controls took effect. Amtagvi powers second-quarter beat
• Positive Sentiment: Pipeline and regulatory catalysts expanded: The FDA granted Fast Track Designation to lifileucel for soft tissue sarcomas. Investors are also anticipating clinical updates in non-small-cell lung cancer and melanoma at upcoming medical conferences, potentially supporting larger future markets. Iovance pipeline update
• Neutral Sentiment: Buyout speculation and options activity: Media reports cited increasing acquisition speculation, while call-option volume was approximately 64% above average. Neither indicates a confirmed transaction, so these developments may amplify volatility without changing Iovance’s fundamentals. IOVA buyout speculation
• Negative Sentiment: Profitability remains a risk: Iovance still posted a $47.3 million net loss and continues to carry substantial research and development expenses. Management is reviewing its $350 million–$370 million 2026 revenue outlook rather than raising it immediately, leaving some uncertainty around the pace of growth and the path to profitability.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical?stage biotechnology company specializing in the development and commercialization of tumor?infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN?144), is an autologous TIL therapy in late?stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next?generation TIL programs such as LN?145 for cervical and other human papillomavirus (HPV)?related cancers, as well as exploratory studies in head and neck, non?small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor?reactive lymphocytes.